First half 2011 Results and Perspectives



First Half 2011 Results Presentation – August 30, 2011

Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.

The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.

SIPSEN Innovation for patient care

Safe Harbor

The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current crisis, which could in turn erode the local competitiveness of the Group's products relative to competitors operating in local currency, and/or could be detrimental to the Group's margins in those regions where the Group's drugs are billed in local currencies.

In a number of countries, the Group markets its drugs via distributors or agents: some of these partners' financial strength could be impacted by the crisis, potentially subjecting the Group to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by the crisis and where the Group sells its drugs directly to hospitals, the Group could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full.


Finally, in those countries in which public or private health cover is provided, the impact of the financial crisis could cause medical insurance agencies to place added pressure on drug prices, increase financial contributions by patients or adopt a more selective approach to reimbursement criteria.

All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.

3 Ipsen – August 30, 2011 – First Half Results



Today...



Introduction

Marc de Garidel Chairman & CEO





H1 2011, a strong performance throughout

5.2%¹ drug sales growth, driven by : • Robust specialty care growth, up 7.9%¹ y-o-y

20.7%² reported operating margin, up 15.1% y-o-y

One-off costs related to the implementation of the new strategy (-€8.7m) partly offset by proceeds from the favorable outcome of a litigation (+€17.2m)

24.7%² recurring adjusted³ operating margin, up 27.1% y-o-y

Recurring adjusted³ EPS of €1.27, up 32.3% y-o-y

€132.0m net cash position as at June 30, 2011


6 Ipsen – August 30, 2011 – First Half Results

NOTE 1 : excluding foreign exchange impacts NOTE 2: in percentage of Group sales NOTE 3 : before non recurring elements particularly related to the preparation and implementation of the Group's strategy


H1 2011 sales: robust specialty care, resilient primary care

Sales in € million

SIPSEN



SIPSEN (((())) Group's Sales driven by regions other than G5



European G5

Specialty care sales growth offset by tougher competitive environment, notably in French Primary care and government measures in Germany and Spain

- Other European countries
 Sustained volume growth, particularly in Switzerland, Russia, Austria and Ukraine
- North America Continued penetration of Somatuline[®] and Dysport[®]

 ROW Strong volume growth in Algeria, Australia, Columbia and China

Detailed H1 2011 Results

Claire Giraut EVP, Chief Financial Officer






Summary of H1 2011 P&L and evolution

In million euros	H1 2011	H1 2010	Growth (%)
Sales	583.1	553.9	+5.3%
Total Revenues	619.4	585.7	+5.8%
Operating Income	120.8 _{20.7%}	104.9 _{18.9%}	+15.1%
Recurring adjusted ² operating income	143.9 _{24.7%}	113.2 _{20.4%}	+27.1%
Consolidated Net Profit (attributable to Ipsen shareholders)	91.7	75.5	+21.4%
Fully diluted EPS	€1.09	€0.90	+21.1%
Fully diluted recurring adjusted ¹ EPS	€1.27	€0.96	+32.3%

SIPSEN Involution for patient care Other revenues evolution

Other Revenues evolution: +14.4% or +7.1% excluding Inspiration Inc. l 36.3 4.2 31.7 +96.0% 2.1 14.1 in € million 16.9 (16.8)% 18.0 + 42.2% 12.7 H1 2011 H1 2010 Other revenues Milestones Royalties received 11 Ipsen – August 30, 2011 – First Half Results

- Royalties Received Royalties received in H1 2011 doubled with increased royalties from Medicis, Galderma and Menarini
- Milestones
 Decrease mainly due to accelerated recognition of 2010 taspoglutide Deffered Revenues
- Other revenues Invoicing of OBI-1's development costs to Inspiration Inc. and income from the Group's Co-promotion contracts in France




SIPSEN (((())) One-off costs related to the preparation and implementation of the strategy


One-off costs linked to the new strategy announced on June 9



Recurring adjusted¹ Operating Income has improved by 27.1 %

SIPSEN





SIPSEN Innovation for patient care

Balance sheet

In € million Assets	;		Liabilities					
_	2010	H1 2011		2010	H1 2011			
Goodwill	299.1	290.7	Equity	1 077.2	1 072.8			
Investment in associated companies (incl. Goodwill Inspiration Inc.)	57.9	49.4	Minority interests	2.0	2.2			
Property, Plans & equipments	282.3	275.2	Total Equity	1 079.2	1 075.0			
Intangible assets	166.5	182,7	Long-term financial debts	15.3	17.1			
Other non-current assets	232.6	253.0	Other non-current liabilities	250.6	235.0			
Total non-current assets	1 038.4	1 050.9	Other current liabilities	324.7	337.4			
Total current assets	639.8	624.5	Short-term debts	7.7	10.5			
Incl. Cash and cash equivalent	178.1	159.6	Liabilities / discontinued operations	0.7	0.5			
Discontinued operations	-	-						
Total assets	1 678.2	1 675.5	Total Liabilities	1 678.2	1675.5			
Net Cash	156.0	132.0						

16 Ipsen – August 30, 2011 – First Half Results


Cash flow statement

In million euros	H1 2010	H1 2011
Cash Flow before change in working capital	98.6	123.8
Deferred revenues from partnerships	53.1	3.7
Increase/ Decrease in working capital	(17.0)	(30.2)
Net cash flow generated by operating activities	134.7	97.3
Investment in Tangible and Intangible assets	(25.5)	(44.2)
Investment in Inspiration	(57.6)	-
Subscription in Inspiration's bonds	(35.5)	(0.8)
Others	(5.6)	(3.1)
Net cash flow used in investing activities	(124.3)	(48.1)
Net change in borrowings	(0.2)	(0.2)
Dividends paid	(62.3)	(66.5)
Others	(1.0)	(0.4)
Net cash flow used in financing activities	(63.4)	(67.1)
Discontinued operations	(0.0)	-
Change in cash and cash equivalent	(53.0)	(17.9)
Impact of exchange rate fluctuations	11.7	(5.0)
Closing cash & cash equivalents	164.1	155.0
Closing Net Cash	142.1	132.0

17 Ipsen – August 30, 2011 – First Half Results



Deferred revenues



Main evolutions

- 2010: accelerated recognition of the remaining taspoglutide deferred revenues from Roche
- H1 2010: important milestones revenue from Inspiration (\$50m) and Menarini (€18m)



H1 2011, a strong performance throughout

5.2%¹ drug sales growth, driven by :
Robust specialty care growth, up 7.9%¹ y-o-y
Resilient primary care

20.7%² reported operating margin, up 15.1% y-o-y

One-off costs related to the implementation of the new strategy (-€8.7m) partly offset by proceeds from the favorable outcome of a litigation (+€17.2m)

24.7%² recurring adjusted³ operating margin, up 27.1% y-o-y

Recurring adjusted³ EPS of €1.27, up 32.3% y-o-y

€132.0m net cash position as at June 30, 2011


19 Ipsen – August 30, 2011 – First Half Results

NOTE 1 : excluding foreign exchange impacts NOTE 2: in percentage of Group sales NOTE 3 : before non recurring elements particularly related to the preparation and implementation of the Group's strategy

Group strategy – Execution on track

Marc de Garidel Chairman & CEO








Implementation: main milestones to success

2011	2012	2013	2014	2015
Define strategyMerge R&D	R&D « PoC » machine implemented	Somatuline [®] New device rolled out globally	TASQ filed in Europe	Inspiration option assessment
Reinforce Uro- oncology franchise (TASQ)	Barcelona R&D site closed	Dysport [®] A.& P. L.L spasticity filed	Somatuline [®] F. NET filed in the US	Dysport [®] P.U.L filed in the US
Dysport [®] CD CTA ¹ filing in China	French primary care commercial activities	Dysport [®] NDO Ph III initiated	Somatuline [®] NF NET filed WW	5 new Pre clinical candidates (vs.
Somatuline [®] Acromegaly	partnered	Smecta [®] EDL assessment (China)	Dysport [®] A.U.L filed	June 2011) O/W 3 reach POC
CTA ¹ filing in China	IB1001 filed in the USA	OBI-1 Acquired H. filed in the US	Dysport [®] NG filed	Smecta [®] EDL assessment (China)
 New extended Executive Committee 	OBI-1 PhIII (Acquire H) enrollment completed	d	Dysport [®] P.U.L filedin Brazil	
staffed Franchise org.	·		Inspiration option assessment	
implemented	OB-1 PhIII Congenital H. initiated		Smecta [®] EDL assessment (China	a)
IB1001 filed in Europe	US platform reorganized			,
22 Ipsen – August 30, 2011 – First	st Half Results		NOTE 1: C	TA or filing for Clinical Trial Authorization

Subject to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation

Executive Committee recruitment completed





8 IPSEN



Progress update

Increase Focus R&D	 Barcelona R&D site: all administrative and employee-related procedures required to close the R&D are completed
	 R&D programs being aligned with strategic priorities: 5 programs stopped¹ 4 additional programs to be stopped before year-end
Footprint US	 Move to the east coast initiated Target completion date: January 1st, 2012
Other	 Primary Care France: On-going preliminary contacts with potential partners Organizational change: On-going discussions with workers council

²³ Ipsen – August 30, 2011 – First Half Results

Invest to grow: a rich Ph III program

			Phase 1	Phase 2	Phase 3	Filing	→
	Dysport [®] - Spasticity PUL	÷					
	Dysport [®] - PLL	H					
	Dysport [®] - Spasticity AUL	÷					
Dysport [®] Neurology	Dysport [®] - Spasticity ALL	+		Glabellar Lines			
Neurology	Dysport [®] - Next Generation	÷		Giabellar Lines	Cervical Dystonia		
	Dysport [®] - NDO						
	Fipamezole - Dyskinesia						
	Somatuline® - Acromegaly Japan						
Somatuline [®] Endocrinology	Somatuline® - Non Functioning NET	+					
Endocrinology	Somatuline® - Functioning NET - US	H					
Decapeptyl [®] Oncology	TASQ CRPC (Active Biotech)					 	
Hemophilia	IB1001 (Inspiration Inc.)						
(Inspiration)	OBI-1 (Inspiration Inc.)	+				1 1 1 1	


10 on-going phase IIIs, 4 for NMEs, 6 for life cyle management

25 Ipsen – August 30, 2011 – First Half Results

SIPSEN Innovation for patient care



Ipsen differentiated from 10 peers¹ in terms of Ph III intensity²



Ipsen and its peers¹ - Intensity of Ph III programs

NOTE 1 : 10 peers selected with a criteria such as Sales, EBIT, R&D to sales ratio, PE, Headcount, Therapeutic Areas, Geographical reach... Peers include: Lundbeck, Meda, Almirall, Shire, Biogen Idec, Allergan, Novo Nordisk, Merck Serono, Actelion and Orion NOTE 2 : Based on available and disclosed information as of august 2011 Note 3 : Number of Ph III for a single indication



Leveraging Ipsen's pan European infrastructure for hemophilia

European partnership signed with Inspiration for the commercialization of IB1001 and OBI-1

- MAA filing in Europe for IB1001 (recombinant Factor IX) in Europe expected before year end
- Ipsen to act as Inspiration's exclusive commercial agent (FIX and OBI-1)
- Business Unit leveraging Ipsen's existing resources combined to Inspiration's expertise
- Inspiration to:
 EBIT neutral for Ipsen:
 - Book sales Book SMM costs
 - Bear all costs
- Book corresponding Other Revenues (re-billing)
- Potentially attractive commercial opportunity:
 - 2008 FIX European market: c.\$380m¹or c.44% of ww market
 - 2020 FIX European market¹: c.\$680m¹

Exclusive commercial agent in a total of 53 countries



A plug-and-play commercial organization for Inspiration's hemophilia products in Europe, increasing Ipsen's hemophilia market knowledge and presence

27 Ipsen – August 30, 2011 – First Half Results

NOTE 1 : 2008 World Wide Coagulation market, MRB; Internal Estimates


FY 2011 Outlook and Newsflow

Marc de Garidel Chairman & CEO





Revised 2011 financial objectives



NOTE 1 :before non recurring elements particularly related to the preparation and implementation of the Group's strategy

2011 objective excludes any potential non recurring items

29 Ipsen – August 30, 2011 – First Half Results

SIPSEN Innovation for patient core

News flow – upcoming catalysts

Filing of IB1001 in Europe (H2 2011) and in the US (H1 2012)

Implementation¹ of Franchise based organization

New future for Primary Care France and Dreux manufacturing plant

Maximize value of Apokyn[®] and Increlex[®] in the US while meeting its obligations to patients and partners

New US platform fully operational



2011, a year of transition...

...with a strong H1 financial performance...

...despite one-off restructuring costs...

...related to the implementation of the new strategy...

...and an increased drug sales objectives

31 Ipsen – August 30, 2011 – First Half Results

Thank you.




Q&A.



Appendices





SIPSEN Innovation for patient care

H1 2011: from Published EPS to recurring adjusted EPS

	30 June 2011	restated		Plus		30 June 2	2011
in million euros		% Sales	Effects of acquisitions in North America ⁽¹⁾	Expenses linked with the strategy announced on 9 June ⁽²⁾	Other non- recurring items ⁽³⁾		% Sales
Revenue	619.4	106.2%				619.4	106.2 %
Cost of goods sold Research and development expenses Selling expenses General and administrative expenses Other operating income and expenses Amortisation of intangible assets Restructuring costs Impairment losses	(120.9) (105.8) (205.6) (42.6) 0.9 (1.6) (0.0) 0.0	-20.7% -18.1% -35.3% -7.3% 0.2% -0.3% -0.0%	(1.6)	(10.6) (28.1)	17.2	(120.9) (105.8) (205.6) (42.6) 7.5 (3.1) (28.1) 0.0	-20.7% -18.2% -35.3% -7.3% 1.4% -0.5% -4.8%
Operating income	143.9	24.7%	(1.6)	(38.7)	17.2	120.8	20.7%
Financial income/(expense) Income taxes Share of profit/loss from associated companies	1.2 (33.7) (4.1)	0.2% -5.8% -0.7%	0.6	12.8	(5.9)	1.2 (26.2) (4.1)	0.2% -4.5% -0.8%
Net profit from continuing operations	107.3	1 8.4 %	(0.9)	(25.9)	11.3	91.7	15.6%
Profit from discontinued operations	0.2	0.0%				0.2	0.0%
Consolidated net profit	107.5	18.4 %	(0.9)	(25.9)	11.3	91.9	15.7%
 attributable to shareholders of Ipsen S.A. attributable to minority interests 	107.3 0.2					91.7 0.2	
Diluted earnings per share (in euros)	1.27					1.09	

(1) Effects of the allocation of goodwill resulting from transactions by the Group in North America.

(2) Expenses linked with the strategy announced on 9 June include:

certain non-recurring fees incurred during the preparation and early implementation of the strategy announced on 9 June 2011,

non-recurring expenses linked with restructuring, corresponding to the closure of the site in Barcelona and the transfer of the Group's North American commercial subsidiary to the East
 certain expenses linked with changes within the Group's Executive Committee.

(3) Other non-recurring items include the damages received by the Group after the enforceable court decision relating to the trade dispute between the Group and Mylan.

36 Ipsen – August 30, 2011 – First Half Results



FY 2010: from Published EPS to recurring adjusted EPS

In million euros	2010 Actual Plus				2010 Actual Recurring adjusted		
	Value	% Sales	Roche	Impairment	Other (2)	Value	% Sales
Net Sales	1 100.2	100.0%				1 100.2	100.0%
Other Revenues	70.1	6.4%				70.1	6.4%
Total Revenues	1 170.3	106.4%				1 170.3	106.4%
Cost of goods Sold	-236.2	-21.5%			-2.7	-238.9	-21.7%
R&D	-221.1	-20.1%				-221.1	-20.1%
SMM	-422.8	-38.4%				-422.8	-38.4%
G&A	-98.3	-8.9%				-98.3	-8.9%
Other (1)	37.1	3.4%	-48.7	-11.3	17.0	-6.0	-0.5%
Impairment losses	-100.2			100.2		0.0	
Operating Result	128.8	11.7%	-48.7	88.8	14.3	183.2	16.6%
Financial Result	-3.4	-0.3%		1.6	-4.3	-6.1	-0.6%
Income Tax	-17.0		7.6	-16.0	-4.8	-30.2	
Effective tax rate	-13.5%					-17.2%	
Share of loss	-12.8			5.9	-1.4	-8.3	
Income from continuing operations	95.7	8.7%	-41.2	80.3	3.8	138.6	12.6%
Income from discontinued operations	0.0						
Consolidated net profit	95.7	8.7%	-41.2	80.3	3.8	138.6	12.6%
Fully diluted EPS	1.13		-0.49	0.95	0.05	1.64	

(1) Other operating income and expenses, Amortizations of intangible assets and Restructuring costs

(2) Impacts from Purchase Price Accounting (PPA) and certain other costs

37 Ipsen – August 30, 2011 – First Half Results